A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...